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Developing vaccines to biothreat agents presents a number of challenges for discovery, preclinical development, and licensure.
The need for high containment to work with live agents limits the amount and types of research that can be done using complete
pathogens,andsmallmarketsreducepotentialreturnsforindustry.However,anumberoftools,fromcomparativepathogenesisof
viral strains at the molecular level to novel computational approaches, are being used to understand the basis of viral attenuation
and characterize protective immune responses. As the amount of basic molecular knowledge grows, we will be able to take
advantage of these tools not only to rationally attenuate virus strains for candidate vaccines, but also to assess immunogenicity
and safety in silico. This review discusses how a basic understanding of pathogenesis, allied with systems biology and machine
learning methods, can impact biodefense vaccinology.
1. Vaccines for Biodefense
We have traditionally associated the term “Biodefense” with
military applications. However, since October 2001 when
anthrax spores were sent in envelopes through the US
Postal Service, our understanding of biodefense has shifted
signiﬁcantly. We now see biodefense as the process to
protect both civilian and military populations. It has become
clear that many highly pathogenic microorganisms can be
considered as either agents of biological warfare or naturally
occurring emerging disease threats. In addition, we consider
bioterrorism from varying points of view, including public
health threats, veterinary threats, and agricultural threats.
Takentogether,theycanbeconsideredtobe“biothreats”.The
biodefense ﬁeld represents a unique challenge for vaccine
development as the traditional economic models for vaccine
development are based on large populations purchasing a
vaccine to protect against common infectious diseases in
order that a vaccine pharma can make a proﬁt. The situation
in biodefense is very diﬀerent where the goal is to stockpile
vaccineswiththehopethattheywillneverbeused.Relatively
small markets, combined with the diﬃculties of working
with many of these agents—many of which require biosafety
level 3 or 4 containment—means that there are currently
no vaccines licensed for general use in the United States
and most other countries for nearly all of the biothreat
agents. There are major hurdles to the development of
biodefense vaccines. In addition to the traditional issues of
identifying protective immunogens and platforms to deliver
the vaccines, there are major diﬃculties in undertaking
eﬃcacy studies as most of the diseases are rare, occur spo-
radically,orarenotfoundnaturally.Accordingly,emphasisis
being placed on appropriate animal models to demonstrate
eﬃcacy in support of licensure. However, at this time,
no vaccine has been approved based on animal eﬃcacy
trials only. Nonetheless, a signiﬁcant amount of data are
being accumulated describing the molecular basis of disease,
which provides a strong foundation for continuing product
development. The current state of biodefense vaccines in
clinical development is summarized in Table 1.2 Journal of Biomedicine and Biotechnology
Table 1: Current status of vaccines in clinical trials against priority pathogens and potential biothreat agents. Data for the table come from
http://www.clinicaltrials.gov/ and other sources as indicated. Many vaccines are in preclinical development, including a number of candidate
vaccines for Lassa virus [1–6] and Sin Nombre [7, 8] virus, both being important hemorrhagic fever viruses.
Virus Disease Candidates in clinical development
Dengue
Dengue fever, dengue
hemorrhagic fever, and
dengue shock syndrome
Live attenuated
Live chimeric (yellow fever 17D backbone)
Recombinant subunit (envelope protein)
DNA plasmid
Molecular attenuated based on infectious
clone-derived virus
Ebola and Marburg
viruses
Ebola hemorrhagic
fever/Marburg
hemorrhagic fever
Recombinant adenoviral vector
Recombinant Vesicular stomatitis virus
vector [9]
DNA plasmid
Junin virus Argentine hemorrhagic
fever
Live-attenuated candid #1 currently used in
Argentina.
Candid #1 has had investigational new drug
status in USA [10].
Rift Valley fever virus Rift Valley fever
Inactivated Rift valley fever investigational
new drug status in USA
Live-attenuated MP-12
SARS-CoV Severe acute respiratory
syndrome Inactivated SARS Coronavirus
Variola virus Smallpox
Vaccinia virus vaccines were successfully
used to eradicate smallpox. Continuing
eﬀorts to develop and reﬁne vaccines to
reduce incidence of adverse eﬀects, Modiﬁed
Vaccinia Ankara (MVA), LC16m8, and so
forth.
Venezuelan equine
encephalitis virus Viral encephalitis
Live-attenuated TC-83, investigational new
drug status in USA
Formalin-inactivated C-84, investigational
new drug status in USA
Molecular-attenuated infectious
clone-derived V3526
The advent of the 21st century has seen our exper-
tise in molecular biology increase exponentially. With the
increasingaﬀordabilityofhigh-throughputsequencing,con-
cepts such as reverse vaccinology—using pathogen genome
sequences to produce peptides and nucleic acids for vac-
cine testing—have become more established [11, 12]. As
our understanding of the molecular basis of pathogenesis
continues to grow, coupled with large numbers of genome
sequences for various pathogens becoming available and
novel bioinformatics tools to facilitate their analysis, we are
heading towards a position where vaccines can be rationally
designed based on our molecular knowledge. This includes
selection of an optimum immunogen and delivery system
to maximize the host protective immune response rather
than empirical approaches that were used for much of the
20th century. The continuing generation of high-throughput
datasets characterizing high-priority biodefense and public
health pathogens, and their host responses in the post-
genomic era, will require novel bioinformatic techniques.
These computational approaches will allow a more complete
and thorough understanding of infection and pathogenesis,
and greatly facilitate rational vaccine design. This review
describessomeofthesemethodsandhowtheycanbeusedin
the development of novel vaccines against biothreat viruses.
2. Global Host-Pathogen Interactionsof
Biothreat Agents
Techniques such as microarray expression proﬁling, 2D gels,
automated spot picking and peptide sequencing, and other
high-throughput methods have revolutionized the study of
virusinteractionswiththehostcell.Inparticular,microarray
analysis has proven a very useful tool in the emerging virus
and biodefense ﬁeld as the RNA extraction process facilitates
removalofsamplesfromthebiosafetylevel3(BSL-3)orBSL-
4 laboratory where only inactivated samples are allowed to
leave biocontainment.
A successful vaccine must be both safe and immuno-
genic. Many pathogenic viruses interfere with the devel-
opment of a protective immune response by preventingJournal of Biomedicine and Biotechnology 3
the activation of key aspects of the immune response,
from inhibition of IRF-3 phosphorylation to block type-
I interferon synthesis to sequestering MHC-I in the cell
to prevent display of virus-derived peptides. A central
feature of many biothreat pathogens is the infection of
macrophages and dendritic cells as the primary target for
replication. Infection of these cell types enables viruses to
prevent immune response development at an early, central
stage. For example, dendritic cells infected with Lymphocytic
choriomeningitis virus (LCMV), an Old World arenavirus
used to infect macaques as a model for Lassa fever, lead
to downregulation of MHC-II on the dendritic cell surface,
inhibiting the ability of these cells to present antigen and
develop the adaptive immune response [13] while Marburg
virus infection of macaques leads to downregulation of
MHC-II on dendritic cells in the spleen [14]. Eﬀects such
as these are common following infection with these viruses
resulting in signiﬁcantly impairment of the host to develop
ap r o t e c t i v ei m m u n er e s p o n s ea ta ne a r l ys t a g eo fi n f e c t i o n .
The downregulation of MHC-II has also been observed in a
microarray study of PBMCs from LCMV-infected macaques
with pathogenic virus inducing a greater downregulation
than infection with attenuated virus [15]. Interestingly,
MHC-II was upregulated in liver tissues [16], highlighting
the importance of animal models and role of the host as
having diﬀerent functional systems, which may respond
diﬀerently to a similar challenge at the molecular level.
The contributions that host-pathogen interaction pro-
ﬁling can make to vaccine development are exempliﬁed
by a study which determined that substitution of a single
amino acid in the VP35 protein of Ebola virus is suﬃcient
to disrupt the viral inhibition of innate immune signaling,
while maintaining the ability to replicate to wild-type levels
in cell culture [17]. Similarly, deletion of an entire multigene
family, with a hypothesized role in modulation of the
interferon system, still results in viral replication [18]. If
the viral proteins responsible for mediating inhibition of
the host immune response can be determined, then targeted
mutationscanbemadetodisrupttheseeﬀects,counteracting
the inhibition of the host immune response and allowing
the host to induce either an innate and/or a protective
immune response. In this way, live-attenuated viruses may
be developed for further characterization as novel vaccine
candidates.
Large DNA viruses, such as Variola virus, the causative
agent of smallpox, contain large genomes of almost 200kb
encoding several genes that modulate the host immune
response. In these situations, individual proteins may have
a single function only, allowing entire genes to be knocked
out to attenuate the virus, as is seen with vaccinia virus.
In some cases, suﬃcient redundancy may exist requiring
the deletion of multiple genes or whole genome sections
to suﬃciently attenuate the virus. For example, African
swine fever virus, from another family of large DNA viruses,
causes a hemorrhagic disease in domestic pigs and encodes a
number of genes that modulate the host immune response.
One such gene, A238L, encodes a protein which inhibits the
transcription factor NF-κB, a central regulator of inﬂam-
mation and the innate immune response [19]. However,
deleting this gene does not cause any diﬀerence in porcine
disease [20]. Similarly, deletion of an entire multigene family
with a hypothesized role in modulation of the interferon
system still results in viral replication [21, 22].
However, all of the current biothreat viruses, with the
exception of Variola virus, are RNA viruses, with limited
coding capacity and proteins that have multiple functions. In
these cases, the deletion of entire genes may result in a non-
viable virus. This illustrates the importance of identifying
the individual residues/regions responsible for speciﬁc virus-
host interactions. If speciﬁc residues are identiﬁed that
are important in determining virulence or in modulating
the host immune response, but do not interfere in the
critical functions of viral replication, mutation of these sites
may lead to novel vaccine candidates. For example, recent
mappingoftheNipahvirusPgenehasidentiﬁedaregionthat
is required for inhibition of STAT-1 signaling, but without
disrupting its function as a cofactor for the viral polymerase
[23].
The use of global approaches, particularly microarray
gene expression technology, has provided a wealth of infor-
mation detailing the host responses to infection. While these
data are often limited to transcription rather than expression
at the protein level, they have provided signiﬁcant insight
into which classes of host genes are up- and downregulated
in response to virus infections. A novel application of this
technology is to use the diﬀerentially expressed genes as
a marker of upstream transcription factor activation using
bioinformatics tools such as CARRIE [24, 25]. In this way,
host signaling pathways activated or repressed by virus
infection can be inferred and studied further, in particular
those inhibited by virus-induced proteins that are critical in
the pathogenesis of the virus (see below).
3.ComparativeMolecular Pathogenesis
The study of virus-host interactions has helped to identify
host proteins required for particular stages in the virus
life cycle. These studies have also identiﬁed innate immune
mechanisms that are suppressed during infection. Identi-
fying such cellular proteins may allow the development of
novel therapeutics, for example, by inhibiting a cellular
kinase required for viral entry or replication [26–28].
However, it is likely that these studies may not provide
the key information required to aid the development of
novel vaccines as elucidating correlates of protection is not
possible if the study compares candidate vaccine-infected
versus mock-infected groups without including wild-type
virulent virus-infected groups or vice versa. Currently, there
are few high-throughput systems-level studies employing
these types of comparisons in vivo. Analyses of human
transcriptional responses to the yellow fever 17D vaccine
have provided signiﬁcant insights into the host response to
this attenuated virus [29], but such studies, not surprisingly,
lack inclusion of the human response to Asibi virus (the
wild-type parent to vaccine strain 17D) and limit our
knowledge of the molecular basis of attenuation of 17D
virus. However, studies using virulent/attenuated pairs, such4 Journal of Biomedicine and Biotechnology
as LCMV WE/Armstrong infection in macaques [15, 16],
allow one set of responses to be “subtracted” from the other,
ﬁltering the dataset down to a more manageable size for
further analysis and potential correlation of transcriptional
proﬁles with pathogenesis or protection.
As higher-throughput sequencing becomes ever more
aﬀordable, whole genome sequencing of many virus strains
and species is becoming more commonplace. Many of these
types of study have been undertaken from an epidemiologi-
cal perspective in order to trace the natural history of virus
strains and determine and predict their spread. However,
these approaches have potential important applications in
the ﬁeld of vaccinology. Genomic sequence analysis of large
numbers of naturally occurring ﬁeld strains of viruses will be
important in the process to identify speciﬁc mutations that
correlate with diﬀerences in pathogenicity of these viruses,
and subsequently the process of attenuation.
Comparing the cellular responses to infection by virulent
and attenuated viruses has provided a large amount of
information on the molecular basis of pathogenesis that may
have application to developing correlates of protection. A
signiﬁcant trend that seems to be emerging is that infection
withattenuatedvirusespromotesastrongimmuneresponse,
while these events are suppressed in virulent infection.
A number of virus pairs have been used for these types
of analyses. A microarray study of mouse brain tissue
following infection with wild-type or a laboratory-adapted
strain of Rabies virus revealed extensive activation of the
inﬂammatory response and the type-I interferon system in
mice infected with the attenuated virus [30].
Studies using Pichind´ e virus, a guinea pig model for
Lassa fever, have taken advantage of two passage variants of
the virus which cause either a severe hemorrhagic fever or
a mild, self-limiting infection from which animals recover
[31, 32]. Proteomic and kinomic level studies using this
system have been analyzed using pathway analysis and have
shown that infection with the attenuated virus induced
signiﬁcantly more cellular signaling events and immune
response activation than infection with the virulent virus,
which more closely resembles patterns of protein expression
and kinase activity seen following mock infection [33–
35]. These systems-level analyses can be used to generate
hypotheses and tested using pathway-focused assays. Anal-
ysis of NF-κB family activity showed increased expression
and DNA binding of a transcriptionally repressive NF-κB
protein following virulent infection [36] consistent with
observations that pathogenic arenavirus infection fails to
activate cells.
The genomes of the virulent and attenuated Pichind´ e
viruses have been sequenced and the amino acid diﬀerences
between them identiﬁed [37]. The striking diﬀerences in
phenotype are caused by a small number of mutations,
with three amino acid diﬀerences in the envelope glyco-
protein precursor, one in the nucleoprotein, and ﬁve in
the polymerase. Interestingly, while the nucleoprotein has
been shown to play an important role in the inhibition of
interferon induction [38, 39], the mutation observed in the
Pichind´ ev i r u snucleoprotein does not inhibit this function
[37]. Taken together with the observation described above
that a single amino acid in the VP35 protein of Ebola virus
is suﬃcient to disrupt the viral inhibition of innate immune
signaling, it suggests that modulation of immune function is
not the sole determinant of pathogenicity for this virus. The
recent development of an infectious clone system [40]w i l l
allow further characterization of the roles of these mutations
and shed light on the relation of individual amino acid
changes to arenavirus pathogenesis.
Similar ﬁndings have been reported using non-high-
throughout assays. A number of studies have compared
Lassa virus with the related naturally nonvirulent arenavirus
Mopeia virus. Infection of monocytes, targets of arenavirus
infection in vivo and central mediators of the development
o fap r o t e c t i v ei m m u n er e s p o n s e ,w i t hLassa virus does
not result in cell activation or production of TNF-α or IL-
8, and consequently the host immune response to virus
infection is inhibited. In contrast, IL-8 production is not
suppressed and interferon signaling is activated in Mopeia
virus-infected cells, allowing the host immune response to
be induced [41, 42]. Dendritic cells, which are professional
antigen-presentingcells,arealsotargetsofhemorrhagicfever
virusinfection.Lassavirusinfectionofdendriticcellsinhibits
upregulationofthecorrectcell-surfaceexpressionofproteins
involved in antigen presentation, adhesion, or activation,
again inhibiting the development of the adaptive immune
response [43]. Observations of Lassa fever patients demon-
strated higher IL-8 and interferon-inducible protein 10 levels
in patients who recovered from infection compared to those
with fatal outcome [44], which corroborates in vitro studies
suggesting that functional impairment of immune responses
contributes to pathogenesis. However, given the ability of
runaway immune responses to cause an immunopathology
or a “cytokine storm”-like disease following infection by
some viruses, immune mechanisms need to be appropriate
and controlled to allow the development of the correct
responses and lead to clearance of the virus. In the case of
SARS coronavirus, a microarray study demonstrated that
early induction of host responses and proinﬂammatory
signaling was correlated with a fatal outcome of infection
in aged mice [45]. Two attenuated variants of Rift Valley
fever virus (RVFV), a Bunyavirus and category A priority
pathogen, have also provided insights into how diﬀerences
in viral genome, host interactions, and pathogenesis can
identify important viral virulence determinants. The NSs
protein mediates the inhibition of the type-I interferon
response, a critical mediator of the innate response to viral
infection important in establishing appropriate secondary
immune developments. The clone 13 strain of RVFV has
a large deletion in the NSs coding region, removing its
ability to inhibit the type-I interferon response, which
leads to a highly attenuated phenotype in mice, but retains
immunogenicity, and is a potential candidate vaccine [46–
49].
Integrating the virus infection data using pathway
analysis and functional systems biology tools can provide
an overview of the similarities and diﬀerences between
infections by either a virulent or an attenuated variant of
a virus. For example, inferring the upstream transcription
factors that are diﬀerentially activated between attenuatedJournal of Biomedicine and Biotechnology 5
and virulent infections from microarray data may allow the
responsible signaling pathways to be identiﬁed. If activation
of a speciﬁc signaling pathway is associated with the expres-
sionofasubsetofgenesassociatedwiththedevelopmentofa
protective immune response, this pathway could be targeted
for stimulation as a novel adjuvant strategy, or its activity
assayed as a proxy for potential eﬃcacy if screening several
vaccine candidates.
While the continued discovery of the types of virulence
determinants discussed above by the study of virus strains
that diﬀer in pathogenesis illustrates the power and sim-
plicity of this approach, the above examples demonstrate
the important point that characterization of the appropriate
immunological events associated with protection diﬀers
from pathogen to pathogen and from model to model. As
datasets from global host-pathogen interaction studies con-
tinue to becomeavailable,novel meta-analysesat thesystems
level may allow particular patterns associated with pathogen,
host, and disease pathology to be observed, which can feed
back into models for vaccine development. At present, most
studies are concentrating on the innate immune response, in
particular the interferon signaling pathway, rather than the
adaptive immune response. The major diﬃculty of all these
studies is undertaking studies on wild-type virulent virus in
human cells due to biocontainment requirements for studies
in cell culture and animal models, while studies in humans
are very hard to undertake as patient samples do not usually
become available until late in the disease course or from
deceased individuals.
4.ApplicationsofSystemsBiology andMachine
LearninginVirus-HostInteractions
High-throughput “omics” experiments provide an almost
overwhelming amount of data for validation and further
studies, which makes interpretation diﬃcult. As such, anal-
ysis is often limited to a heatmap following hierarchical
clustering analysis to obtain a broad overview of the dataset
and the relationships between the treatment groups, with
the transcripts showing the highest fold-changes selected for
conﬁrmation by RT-PCR and further experiments. With the
majority of recent work focusing on either the underlying
molecular biology of virus infection and cellular responses
or disease pathology at the histological level, emerging
bioinformatics tools, and the continued use of experimental
methods that characterize cellular regulation at a number
of levels, from mRNA expression to metabolomics, will
allow these two extremes to be linked, providing a holistic
“systems-level” view of pathogenesis [50]. Importantly, these
levels of increased understanding will be beneﬁcial to many
areas of research, including vaccinology, as we will ultimately
be able to screen vaccine candidates based on the eﬀects
on particular host genes and/or proteins following infection
(e.g., lack of inhibition of interferon signaling pathway) of a
particular cell type, and later in appropriate animal models,
with the vaccine candidates.
Techniques such as k-means clustering can be of use
in “ﬁltering” large numbers of genes down to manageable
sizes for further analysis. In this approach, the diﬀerentially
expressed genes are portioned into a number of clusters
determined arbitrarily. An iterative algorithm then reﬁnes
the clustering until each transcript is in the cluster with the
closest mean average. In this way, transcripts with similar
expression characteristics will collect in the same cluster.
If gene expression analysis is used to compare the cellular
responses following infection with mock, wild-type and
attenuated or candidate vaccine strain viruses, groups of
genes that may be speciﬁcally up or downregulated by a
particular virus variant, will become apparent. These genes
may be selected for further investigation using other meth-
ods. Figure 1 shows a generic example of the type of output
produced following k-means clustering. As can be seen, the
three clusters show groups of genes that are upregulated
following wild-type but not attenuated virus infection, genes
upregulatedasaconsequenceofbothinfections,andacluster
of genes which are upregulated by attenuated but not wild-
typeinfection.Thislattergroupofgenesmayrepresentthose
that are required to initiate a protective immune response
and indicate potential biomarkers of protection.
An approach that is becoming more widely used in
this ﬁeld is that of pathway analysis. Using knowledgebases
of known interactions between proteins, DNA, RNA, and
small molecules, large datasets can be placed into a more
“functional”contextonthebasisoftheirknowninteractions.
Pathway analysis tools such as Cytoscape [51, 52] and the
Ingenuity Pathway Analysis software [53] are increasingly
used to understand protein and gene interactions and con-
struct so-called “signaling networks”, often following char-
acterization of gene and protein expression by microarray
or proteomics analysis. Figure 2 shows an example network
constructed from microarray analysis of viral infection.
These types of approaches have also been used to
analyze interactions and network relationships between
viral proteins as well as to characterize the interaction of
viral proteins with cellular proteins [54–56]. However, to
date, these types of mapping analyses have required high-
throughput yeast two-hybrid type assays to generate the
input data. Consequently, this type of approach may not yet
be suited to the high-throughput identiﬁcation of protein
interaction networks for large numbers of virus strains,
including potentially attenuating mutations. Furthermore,
the yeast 2-hybrid system does not always generate prac-
tical meaningful interactions and a signiﬁcant number of
experimentsarerequiredtosubstantiateproteininteractions.
However, machine learning approaches have been applied
to the determination of protein-protein interactions. In
particular, support vector machines have been used to
predict protein-protein interactions on the basis of sequence
information alone.
Support vector machines (SVMs) are a machine learning
approach which allows binary classiﬁcation following train-
ing of an algorithm on a “test-set” of data. The SVM is
trained on a dataset which includes a number of parameters
where the classiﬁcation is known. The SVM develops an
algorithm that, when given a set of parameters (n)o f
unknown classiﬁcation, can be used to predict the class on
the basis of the training set. The SVM transforms the data,6 Journal of Biomedicine and Biotechnology
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Figure 1: A generic example of analysis using k-means clustering.
Data, such as from an mRNA expression microarray following
mock, virulent, and attenuated infection of cell cultures or animals,
are placed into clusters, on the basis of a similar pattern of
expression to other genes in that cluster; lines represent an
individual transcript. As can be seen, this type of analysis can
quickly determine groups of transcripts which may associate with
pathogenesis or protection.
places it into n-dimensional space, and attempts to separate
the data by class by deﬁning a hyperplane through this
“feature space” (Figure 3). The advantage of these types of
methods is that the number of parameters can be tailored to
strike a balance between what is experimentally feasible and
predictive accuracy. As the number of parameters increases,
classiﬁcation accuracy may improve, but collecting the data
may become less feasible experimentally. With training
sets constructed from known protein-protein interactions
deﬁned experimentally, SVM-based approaches have shown
increasing accuracy for predicting these interactions [57–
59]. Using these approaches, it may be possible to screen
large numbers of protein sequences in silico to elucidate
aminoacidmutationstodisruptprotein-proteininteractions
that may attenuate a virus, such as the single amino acid
substitution that signiﬁcantly attenuated Ebola virus [17].
Computational approaches have also demonstrated their
power in de novo attenuation of viruses. Coleman et al.
coined the term “synthetic attenuated virus engineering”,
SAVE, to describe their approach for attenuating virulent
viruses [60]. Their approach takes advantage of the redun-
dancy of the triplet genetic code and the fact that there
is often a codon usage bias, where particular codons are
used more or less often to code for a particular amino
acid than would be predicted by chance. They developed
a computer algorithm that recoded a given amino acid
sequence at the genetic level, changing the codon pairs to
those which were under-or overrepresented in the wild-type
sequence. Their algorithm also included other features such
as RNA folding-free energy, a factor shown to be implicated
in hostadaptation of inﬂuenza virus [61]. By altering codon
pair usage, they were able to construct a poliovirus that
was attenuated in mice and provided protective immunity
[60]. Of particular interest with this type of strategy is that
the protein sequence remains unchanged from the wild-type
virus. This reduces the likelihood of reduced protection by
the attenuating mutations disrupting important epitopes.
Asdiscussedabove,themajorityofhigh-throughputdata
to emerge from the biodefense ﬁeld has been microarray
mRNA expression data, rather than from high-throughput
protein interaction data that directly lend itself to network
analysis. However, genomics- and proteomics-level analyses
have produced interaction networks that are beginning to
yield some consistent and overlapping signaling pathways
across diﬀerent model systems, and novel computational
approaches are providing alternative strategies for virus
comparison and attenuation.
5.Towards TargetedVaccineDesign
Traditionally, live-attenuated viruses have been developed
by serial passage of wild-type viruses in culture. The live-
attenuated yellow fever 17D and the polio Sabin vac-
cines were developed in this way. However, the attenuated
poliovirus vaccine can revert to virulence and has been asso-
ciated with vaccine-associated poliomyelitis [62]. In recent
years, the yellow fever 17D vaccine has caused a number
of serious adverse eﬀects with a signiﬁcant case fatality
rate [63–65]. Some of these outcomes may be associated
with polymorphisms in the CCR5 chemokine receptor and
RANTES chemokine genes in some vaccinees [66]. This
ﬁnding complicates the vaccine safety ﬁeld. If the vaccine-
associated disease is associated with hostpolymorphisms
rather than with virus reversion, then determining vaccine
safety becomes increasingly complicated and suggests that
in the 21st century each vaccine may become restricted to
individuals with a particular host genetic background.Journal of Biomedicine and Biotechnology 7
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Figure 2: Placing datasets into a functional context using pathway analysis. Example transcriptional expression data were uploaded to the
Ingenuity Pathway Analysis application (http://www.ingenuity.com/), and its knowledgebase was used to construct signaling networks on
the basis of known interactions from the literature. These approaches can allow the visualization of networks associated with viral infection
and identify signaling “hubs” which may act as master switches of the host response.
As high-throughput methods become more aﬀordable,
personalized vaccinology may be a strategy that becomes
more feasible. Personalized vaccinology refers to the ability
to tailor particular vaccines to speciﬁc individuals [67, 68].
If, for example, adverse responses to the yellow fever vaccine
can be attributed to a speciﬁc genetic polymorphism, then
the vaccinee can be screened for this polymorphism, and
decisions whether or not to vaccinate can be made on that
basis.Ifalternatevaccinesareavailable,whichperhapsoﬀera
shorter-lived immunity but without reported adverse eﬀects,
appropriate risk assessments can be made and a course of
action determined, in the best interests of the individual
vaccinee.
The two basic requirements for vaccine design are the
induction of a protective immune response and safety.
Bioinformatics can assist with both of these. Studies of
human responses to the yellow fever vaccine using mRNA
microarrays have revealed the immune pathways responsible
for protection [29, 69, 70]. Unfortunately, as these studies
were performed in human volunteers, there is no directly
comparable dataset following exposure to wild-type yellow
fevervirusinfection.Asdiscussedabove,thisraisesoneofthe
problemsofutilizingsystembiologyinvaccinedevelopment;
namely, studies with candidate and licensed vaccines in
humans are comparatively easy while obtaining samples
from wild-type infections and serious adverse events are very
diﬃcult for a variety of reasons. However, these studies do
reveal signiﬁcant insights at the molecular level into how a
historically very successful vaccine induces protection. These
studies showed activation of several arms of the immune
response but identiﬁed key transcription factors which acted
as “master switches” in immune response development.
Pathway analysis revealed these to be central “hubs”: highly
connected “nodes” in a signaling network. There are a
number of biodefense vaccines in Investigation New Drug
(IND) Status, due to limited studies on safety and eﬃcacy,
which are administered to individuals who are at risk from
the disease. Bioinformatic studies on vaccinees who receive
these IND vaccines may help generate important data that
have application to safety and eﬃcacy.8 Journal of Biomedicine and Biotechnology
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Figure 3: Separation of datasets using support vector machines. In
this representation, three variables are observed for each data point,
leading to a three-dimensional feature space. Transformation of the
data into the feature space allows the two classes of observation to
be split by the hyperplane (grey).
Thesetypesofanalysismayalsoassistinthedevelopment
of novel adjuvants. Microarray studies characterizing the
global host responses to the adjuvants alum, CpG, MF59,
and LTK63 have identiﬁed transcript signatures common
between and speciﬁc to these adjuvants [71, 72]. By under-
standing how these transcriptional responses correlate with
the development of speciﬁc immune mechanisms, appro-
priate pathways could be stimulated with speciﬁc vaccines
to induce the appropriate immune eﬀector functions for
that pathogen: as eﬀorts to design vaccines to be as safe
as possible continue, a potential side eﬀect could be over-
attenuation leading to increased safety at the expense of
immunogenicity and lasting protection. A possible solution
could be the use of novel adjuvants to stimulate the signaling
pathways associated with a strong immunogenic response.
As an example, inﬂammasome activation was found to
be a central regulator of the immune response to yellow
fever vaccine [69]. Interestingly, a novel nanoparticle-based
vaccine delivery method has recently been reported which
includes lipopolysaccharide to activate the inﬂammasome
alongside delivery of a protein subunit vaccine [73]. Com-
bining ﬁndings such as these will be central to future themes
of vaccinology. As our understanding of the correlates of
protection for currently licensed vaccines increases, we may
be able to target speciﬁc cellular pathways to tailor immune
responses to a new generation of highly attenuated, safe
vaccines.
Recently, a machine learning algorithm, based on a
supportvectormachine, wasusedtoidentifypotential corre-
lates of immune protection, with potential transcript-based
indicatorsofcell-mediatedandantibodyresponsesidentiﬁed
[29]. While these ﬁndings require further validation and
comparison with potential indicators for responses to other
vaccines,theysuggestthatbioinformaticscouldprovidetools
to predict immunization outcome soon after vaccination.
Additionally, pathway analysis can be used to screen for
transcriptional responses which are associated with other
diseases or adverse eﬀects, potentially providing a means to
assay vaccine safety in vivo early in the development process.
Currently, a limiting factor in the rational attenuation
of biodefense viruses for vaccine design is in obtaining
datasets from equivalent platforms and model systems,
facilitatingmeta-analysestodeterminepotentialcorrelatesof
attenuation. However, while the virus-host interaction ﬁeld
may not yet be addressable in this way, eﬀorts are being
madetocompileeasilyaccessibledatabasesofviralsequences
for query. One such database has collected over 300 protein
sequences from pathogenic arenaviruses to aid in epitope
discovery studies [74]. Combining these types of databases
with patient data such as antibody titer or disease severity
may allow consistent peptide sequences which correlate with
immune protection to be determined. This type of approach,
combined with computational MHC epitope prediction,
will signiﬁcantly further our ability to rationally develop
immunogenic vaccine candidates.
6. Summary and Conclusions
The increased availability and aﬀordability of high-
throughput technologies, such as whole genome sequencing
and “omics” analyses, will allow the continuing development
of large, multilevel datasets to characterize host responses
to pathogens of diﬀering virulence, and the changes in
viral sequences responsible. As bioinformatics continues
to evolve, and as microbiologists, immunologists, and
vaccinologists become more familiar with the potential of
these technologies, the stage will be set for novel approaches
to vaccine design for biodefense, combining rational
attenuation with immunogenicity and safety testing. By
integrating these approaches early in the process, and using
a combination of in vitro and in silico techniques, vaccine
candidates with the most promise can be selected for further
testing with a greater conﬁdence, and funding can be better
appropriated.
The use of comparative studies between virulent and
attenuated strains could provide a wealth of data to assist
in vaccine development. While many datasets have been
published, comparison across diﬀerent experimental systems
remains an issue. Ideally, cell lines, timepoints, and other
experimental criteria need to be standardized to allow
informed comparison of the results. The ability to perform
meta-analyses across diﬀerent studies could allow a better
understanding of what host responses are required to lead to
along-lastingprotectiveimmuneresponse.Ifadatasetwhich
characterized the host responses to yellow fever vaccine
could be compared with similar datasets showing responses
to other live vaccines, for example, smallpox vaccine and
Junin vaccine, along with response to the appropriate wild-
type agents, we will undoubtedly ﬁnd several “groups” of
similarities and diﬀerences which associate with protection,Journal of Biomedicine and Biotechnology 9
virulence, or type of virus or disease pathology. These
approaches to vaccine design illustrate how vaccinology can
use the data from basic science, and particularly studies of
molecularpathogenesis,todevelopnovelvaccinecandidates.
Byidentifyingcommoncellularresponsestoattenuatedvirus
vaccines, across diﬀerent viral families and diﬀerent wild-
typediseasepathologies,wemaycharacterizeacentral“core”
of responses which are always activated by a historically
successful vaccine, regardless of virus type. These responses
can guide us in the development of novel vaccine candidates
or adjuvants.
As new viruses continue to emerge and the risks from
emerging and remerging pathogens remain, the need for
vaccines against these pathogens remains signiﬁcant. The
introduction and spread of West Nile virus to North America
illustrates how quickly viruses can become established in a
new area and present novel threats to public health [75].
The continuing investment in biodefense and emerging
pathogens will result in even greater amounts of basic
data to input into novel bioinformatics tools. As our
understanding of the molecular determinants of protection
andpathogenesiscontinuestogrow,thedevelopmentofsafe,
eﬀective vaccines to these important pathogens will continue
to accelerate.
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